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SUMMARY
The histopathological and molecular analysis of the synovial tissue has contributed to fundamental advances 
in our comprehension of arthritis pathogenesis and of the mechanisms of action of currently available treat-
ments. 
On the other hand, its exploitation in clinical practice for diagnostic or prognostic purposes as well as for 
the prediction of treatment response to specific disease-modifying anti-rheumatic drugs is still limited. In 
this review, we present an overview of recent advances in the field of synovial tissue research with specific 
reference to the methods for synovial tissue collection, approaches to synovial tissue analysis and current 
perspectives for the exploitation of synovial tissue-derived biomarkers in chronic inflammatory arthritides.
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n	 INTRODUCTION
Data derived from the histopathological analysis of target tissues are an inte-
gral component of current classification 
criteria or routine diagnostic/prognostic 
work-up in several diseases, including can-
cers and immune-inflammatory conditions. 
Relevant examples of the latter include, but 
are not limited to, the analysis of salivary 
glands in Sjögren’s syndrome (1), the kid-
ney in systemic lupus erythematosus (2) 
and the gut mucosa in inflammatory-bowel 
diseases (3). 
This is only partly the case with regard to 
synovial tissue analysis, which still offers 
a relatively limited application in routine 
clinical practice. Although microbiologi-
cal, molecular or histological assessment 
of the synovial tissue can assist clinicians 
in the diagnosis of joint infections, mus-
culoskeletal manifestations in course of 
rare diseases (i.e. sarcoidosis, amyloidosis, 
haemochromatosis, ochronosis, multicen-
tric reticulohistiocytosis) and synovial tu-
mours (4), synovial pathology is still not 
integrated in standard-of-care management 
of most common forms of inflammatory 
arthropathies. No synovial-derived mark-
ers are actually exploited in clinical con-
texts to predict disease onset, diagnosis, 
clinical outcomes, drug toxicity or to guide 
personalized treatment choices in rheu-
matoid arthritis (RA), psoriatic arthritis 
(PsA) and other forms of spondyloarthritis 
(SpA). Thus, beside the established role of 
synovial tissue analysis for pathobiologi-
cal research (5-8), as a source of surrogate 
endpoints for drug development (9) and to 
elucidate the mode of action of treatments 
(10-12), its potential to improve the man-
agement of arthritis in real life settings re-
mains the object of research (13). 
In the following sections, we present a 
critical summary of the main studies that 
have focused on this goal and that have 
contributed to strengthening the scientific 
rationale of this perspective. We have clus-
tered published data according to specific 
phases of arthritis evolution, with primary 
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emphasis on three of those in which valida-
tion of novel biomarkers would be relevant 
in current clinical practice:
1) early undifferentiated arthritis, 
2) arthritis refractory to first line treat-
ments, 
3) arthritis in remission. 
n	 SYNOVIAL PATHOTYPES
The synovium is a specialized connective 
tissue lining the inner surface of diarthro-
dial joints capsules, tendon sheaths and 
bursae. Due to its intrinsic deformability, 
porosity and through the secretory activity 
of its cellular components, it plays a fun-
damental role in physiological joint move-
ment, synovial fluid homeostasis, cartilage 
lubrication and chondrocyte nutrition. 
These functions are supported by its con-
nection with independent anatomic envi-
ronments:
1) the joint cavity, through a superficial 
lining layer of fibroblast- and mac-
rophage-like cells lacking tight junc-
tions and devoid of a basement mem-
brane;
2) the systemic circulation, through small 
blood vessels and lymphatics, control-
ling cell trafficking, plasma ultrafiltra-
tion and fluid clearance;
3) the central nervous system, through sym-
pathetic and sensory nerve fibres regu-
lating vascular tone and nociception. 
Among these structures, a few scattered ad-
ipocytes, macrophages, quiescent/low pro-
liferating fibroblasts (14) and multipotent 
mesenchymal stem cells (15) complete the 
synovial cell architecture in normal condi-
tions. 
Figure 1 - The inflamed synovium in course of arthritis. The general histopathological appear-
ance of the inflamed synovium (large panel, hematoxylin and eosin) in course of arthritis and 
of specific cellular components (small panels, immunostainings) are shown. Inflammatory fea-
tures include hyperplasia of the lining layer, infiltration of the synovial sublining by myeloid and 
lymphoid cells including macrophages (CD68 staining, brown), T lymphocytes (CD3, brown), 
B lymphocytes (CD20, red), plasma cells (CD138, red), dendritic cells (CD83, brown), and new 
blood vessel formation (neoangiogenesis) (CD31, red). 
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The inflammatory process taking place 
in course of RA or SpA leads to detect-
able pathobiological modifications virtu-
ally related to all the above-mentioned 
components (Figure 1). These can include 
dysregulated angiogenesis (16), local re-
cruitment and organization of myeloid 
and lymphoid cells (5, 17), enhanced 
stromal cell proliferation and epigenetic 
changes (14, 18-20), changes induced by 
local haematopoietic-stromal cell cross-
talks (21-23), lymphocyte activation and 
differentiation (19, 24-27). 
Supporting the potential utility of the as-
sessment of synovitis for clinical stratifica-
tion, these processes are not uniformly and 
synchronously captured in the inflamed 
joint, but are characterized by a degree of 
inter-individual heterogeneity (Figure 2). 
This variability is determined by the gra-
dients that delineate the expression level 
of most inflammatory markers and by the 
possible unrelated expression of differ-
ent markers within single tissues (28, 29). 
Strengthening the pathobiological rationale 
of this picture, when synovitis is approached 
multi-parametrically, it is actually possible 
to distinguish gross pathological categories 
that rely on clustered and congruent histo-
pathological and molecular features. This 
general concept, previously proposed in in-
dependent studies (30-33), has been recent-
ly refined through the delineation of four 
primary patterns of synovitis (34):
1) the lymphoid phenotype, character-
ized by enrichment of genes related to 
B/T lymphocyte activation and differ-
entiation, cytokine signalling includ-
ing the Jak/STAT pathway and IL-17 
signalling;
2) the myeloid phenotype, also charac-
terized by processes associated with 
Figure 2 - Synovial tissue heterogeneity. Inter-individual variations of synovial inflammatory features in course of arthri-
tis are shown. High quantitative variability is observed for the degree of lining layer thickness, of sublining infiltration 
by myeloid and lymphoid cells such as macrophages (CD68 staining, brown), T lymphocytes (CD3, brown), B lympho-
cytes (CD20, red), plasma cells (CD183, red), and of new blood vessel formation (CD31, red).
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chemotaxis, TNFα and IL-1β produc-
tion, Toll-like receptor signalling, Fcγ-
receptor meditated phagocytosis;
3) the fibroid phenotype, enriched for 
genes associated with TGFβ and BMP 
signalling, but lacking enrichment of 
any immune system processes;
4) the low inflammatory phenotype, 
showing only enrichment for inflam-
matory response and wound response 
processes. 
It is worth mentioning that, if on the one 
hand these studies provide a solid biolog-
ic substrate for synovial analyses and for 
clinical translation, on the other hand they 
leave unsolved some critical issues. In par-
ticular, since synovial parameters are in-
fluenced by disease activity (35), whether 
these patterns reflect dynamic phases of the 
inflammatory process or stable pathologi-
cal characteristics of specific RA/SpA sub-
sets remains to be defined. 
n	 SYNOVIAL TISSUE BIOPSY
In addition to the inputs derived from ba-
sic comprehension of synovial pathobiol-
ogy, the opportunities to exploit the syno-
vial membrane for biomarker discovery 
have been considerably widened in recent 
years by the development of mini-invasive 
percutaneous approaches allowing tissue 
retrieval across progressive phases of the 
disease. These contemplate blind needle 
biopsy, arthroscopic biopsy and ultrasound 
(US)-guided biopsy (the latter including a 
quick core needle and a portal and forceps 
technical variants). All these techniques 
have been shown to allow large and small 
joint sampling (36-38), to be applicable 
from early stages of the disease (39-41), 
to be well tolerated (38, 42, 43) and to al-
low collection of good quality tissue for 
histopathological analyses (44, 45). De-
spite parallel comparative analyses are 
still ongoing, arthroscopic and US-guided 
biopsies are currently favoured in clinical 
research due to the opportunity of visual-
izing the synovium during the procedure, 
thus increasing sampling specificity, appli-
cability in quiescent joints and repeatabil-
ity after treatment. 
The above technical advancements, di-
rected towards improving accessibility to 
synovial tissue, have been integrated with 
studies focused on the approach to syno-
vial tissue sampling. In particular, since 
synovial analysis relies on retrieval of only 
a few specimens from a single joint, a fun-
damental issue related to its clinical ap-
plicability to systemic diseases is whether 
the synovial membrane in one joint is ac-
tually representative of that seen in other 
joints. In this perspective, Kraan et al. (36) 
analyzed the characteristics of the synovi-
um in paired arthroscopic samples of the 
knee and small joints (wrists or metacar-
pophalangeal joints) in 9 patients with RA. 
Despite marked variation among patients 
for each marker, no differences were de-
tected in the distribution of fibroblast-like 
synoviocytes, macrophages, T cells and 
plasma cells in different anatomic sites. In 
addition, significant correlations were re-
ported in all sublining parameters between 
knee and small joints, supporting the view 
that synovial sublining infiltration in one 
joint can be representative of the systemic 
process in RA.
Due to the intra-tissue heterogeneity of syn-
ovial inflammation, a complementary issue 
that has been the object of intense research 
relates to the amount of tissue required to 
achieve a representative analysis of the in-
flammatory status in each joint. Supporting 
the relevance of analysing multiple areas of 
the joint (rather than multiple sections from 
a single area), Dolhain et al. (46), through 
the immunohistological assessment of 
synovial samples from large joints, demon-
strated that a variance of less than 10% for 
T cell markers and expression of activation 
antigens can be reached when at least six 
different specimens are examined. Accord-
ingly, four to seven random synovial frag-
ments have been shown to allow detection 
of two-fold change in gene expression with 
25% sampling error by quantitative PCR 
(47). More recent studies focused on small 
joints, in which synovial volume is much 
reduced, confirmed the requirement of a 
minimum of four independent samples for 
reliable histopathological analysis, a target 
that can be achieved by US-guided needle 
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biopsy in approximately 80% of the joints 
with grade 3 synovial thickness (48). 
Taken together, these studies suggest that 
representative data can be obtained when 
a limited number of biopsy samples from 
different areas of one joint are investigated 
in RA, supporting the reliability and feasi-
bility of the procedure. Additional work is 
required to generalize further these conclu-
sions to different diseases, techniques and 
markers.
n	 EARLY UNDIFFERENTIATED 
ARTHRITIS: DEVELOPMENT 
OF DIAGNOSTIC BIOMARKERS
A wide discovery platform for the develop-
ment of biomarkers and prediction models, 
still characterized by considerable unmet 
needs, is the early arthritis phase. Since 
early diagnosis and treatment are linked to 
better long-term outcomes (49, 50), the de-
velopment of novel tools able to improve 
the diagnostic performance in patients with 
recent onset joint swelling is actually seen 
as a relevant target with a direct impact on 
current clinical practice.
Several synovial histopathological stud-
ies in the past have contributed to advance 
current knowledge in this direction, either 
indirectly through comparative analyses 
of differentially expressed markers in es-
tablished diseases, or directly through the 
longitudinal evaluation in undifferentiated 
arthritis patients. 
Proof-of-concept evidence supporting 
the possibility to track disease-associated 
changes in situ derives from independent 
cross-sectional studies investigating the 
pattern of knee synovitis in RA and SpA. 
Examples of histological parameters shown 
to be differently expressed are vascular-
ity (51, 52), angiopoietin-2 (53, 54) and 
CD163+ macrophages (52, 55), all shown 
to be significantly increased in SpA vs RA 
synovium; lining layer thickness (51, 52) 
and the MHC-human cartilage gp39 com-
plex (52, 56), augmented in or restricted to 
RA. The existence of differences has been 
strengthened further through comparative 
analysis by pan-genomic microarrays (57). 
Despite these data, however, only a limited 
number of studies have analysed the actual 
diagnostic value of synovial histopathol-
ogy in longitudinal cohorts of patients with 
early undifferentiated arthritis. One of the 
largest data-sets available to date refers to 
the study performed by Kraan et al. (41), 
who evaluated 95 patients with recent on-
set (<1 year) and unclassified arthritis, 
across a follow-up of at least 2 years af-
ter biopsy. Comparison of baseline syno-
vial characteristics of the RA patients vs 
the pooled non-RA patients at the end of 
follow-up by logistic regression identified 
CD38+ plasma cells and CD22+ B cells as 
independent predictors and best discrimi-
nating markers, suggesting that the histo-
pathological analysis of knee synovium 
in patients with early arthritis can be used 
to differentiate RA from other conditions. 
No evidence for a discriminative value of 
sub-lining cell aggregates (dichotomously 
stratified as present/absent) was obtained, 
instead, in another study based on a similar 
experimental setting through the prospec-
tive analysis of 39 undifferentiated arthritis 
patients (39).
While these data suggest a potential role 
of specific synovial markers for early di-
agnostic discrimination, the most likely 
scenario for clinical exploitation could be 
their integration into multivariable pre-
diction models (not necessarily restricted 
to synovial parameters). This concept has 
been challenged by Baeten et al. (58) who 
analysed, in 53 patients with unclassified 
inflammatory arthritis, the diagnostic pre-
dictive value of single histological markers 
(developed from a learning cohort) com-
bined in a multiparameter decision tree. 
Diagnosis, evaluated after a follow up of 
6 months, was comprehensive of RA, SpA 
and other diseases (gout, chondrocalcino-
sis, villonodular synovitis, osteoarthritis, 
multiple myeloma, Sudeck syndrome and 
polymyalgia rheumatica). Despite the wide 
clinical spectrum, the developed algorithm 
(based on the assessment of synovial crystal 
depositions, anti-citrulline staining, stain-
ing for the MHC-human cartilage gp39 
complex, microscopic vascularity, lining 
layer thickness and macroscopic vascular 
pattern) showed an overall positive predic-
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tive value of 81% and higher performance 
compared to a similar multiparameter al-
gorithm exclusively based on classic (clini-
cal, serological, genetic and radiographic) 
diagnostic features.
Further multi-centric prospective studies in 
large patient cohorts and through standard-
ized assessment protocols might contribute 
to promoting translation of these promising 
data into clinical practice.
n	 DISEASE STRATIFICATION: 
DEVELOPMENT OF 
PREDICTIVE BIOMARKERS OF 
RESPONSE TO TREATMENT
Beyond the development of diagnostic bio-
markers, another relevant target of arthritis 
research is the development of new tools 
able to predict response to individual thera-
pies. The rationale of this goal is based 
on the heterogeneity that characterizes 
chronic inflammatory arthritides, both in 
their natural evolution as well as in the re-
sponse to specific drugs. If on the one hand 
patients affected by the same disease can 
show a heterogeneous response to the same 
molecule, on the other, the same molecule 
can induce a similar response in patients 
affected by different forms of arthritis. This 
observation has led to conceive the per-
spective of a parallel taxonomy of chronic 
inflammatory arthritides firmly rooted in 
shared pathogenetic mechanisms and re-
flected in shared response to treatments. 
In this context, the specific opportuni-
ties offered by synovial tissue analysis in 
terms of dissecting molecular aspects of 
disease (compared to clinical or imaging 
approaches), clearly represent a fundamen-
tal resource. Although this concept may be 
applicable to any treatment, biologic thera-
pies have represented a primary research 
platform in recent years, due to unmet clin-
ical needs (overall ACR50 response rate in 
RA is less than 50%) (59), high financial 
costs and their intrinsic pharmacological 
characteristics based on interactions with 
known molecular targets. 
In the next paragraphs, a selection of most 
relevant studies published so far, primarily 
focused on synovial predictors of response 
to anti-TNF and Rituximab in RA, is dis-
cussed.
Predictors of response to anti-TNF
Initial proof-of-concept evidence suggest-
ing the possibility to capture predictive in-
formation based on synovial assessments 
has been provided by van der Pouw Kraan 
et al. (60) who, through large-scale gene 
expression profiling by microarrays and 
pathway analysis in 18 RA patients start-
ing treatment with infliximab, observed a 
positive association between pre-treatment 
synovial inflammatory activity and respon-
siveness. Parallel data from 143 patients 
evaluated through immunohistopatho-
logical analyses could refine this concept 
pointing at baseline synovial TNFα ex-
pression (but not IL1β, IL6 or IL-18) as a 
significant predictor of response (change in 
28-joint Disease Activity Score [DAS28] 
≥1.2 at week 16), accounting, together 
with baseline DAS28, for an increased ex-
plained variance of 17% (61). Integration 
of other histopathological markers (pres-
ence of sublining cellular aggregates) into 
a multivariable model including baseline 
DAS28, serum anti-citrullinated peptide 
antibodies and synovial TNFα improved 
the prediction of clinical response with 
an increased explained variance of 29% 
(62). A significant negative predictive role 
of synovial aggregates for anti-TNF treat-
ment response in RA was instead reported 
in an independent study (86 patients) based 
on aggregate stratification according to the 
degree of lymphoid structural organiza-
tion. Differences in the study population, 
endpoints or in the analytical method may 
account for this apparent discrepancy (63).
Beyond specific results, these data, collec-
tively, strengthen two relevant hypotheses 
(64):
1) the potential added value of synovial 
analysis in the development of predic-
tion models for targeted therapies;
2) the possible value of dissecting and 
focusing on the specific cellular/mo-
lecular targets of a specific drug for the 
identification of predictive biomarkers.
Supporting this concept, recent studies 
based on synovial tissue analysis accord-
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ing to pathotype stratification (see Synovi-
al pathotypes section) confirmed a positive 
association between anti-TNF clinical re-
sponse and the myeloid phenotype, charac-
teristically linked to TNFα-associated gene 
expression modules in RA (34). 
Predictors of response to rituximab
In line with these perspectives, most of the 
studies that evaluated the synovium as a 
potential source of predictors of response 
to Rituximab have focused primarily on B 
cell biology (65-68). Thurlings et al. (66) 
analysed by serial biopsies (baseline, 4, 
16 weeks) and immunohistochemistry the 
synovial tissue of 24 RA patients, inves-
tigating the dynamic relationship between 
CD22+ B cells, CD138+ plasma cells, fol-
licular dendritic cells, macrophages, T cells 
and clinical response. Although none of the 
baseline characteristics of the synovium 
appeared relevant per se, changes between 
4 and 16 weeks in CD138+ plasma cell 
infiltration demonstrated a significant pre-
dictive value for the size of DAS28 change 
at 24 weeks. Similarly, no differences be-
tween responders and non-responders were 
observed by Gutierrez-Roelens et al. (67) 
in baseline synovial distribution of CD20+ 
B cells, CD138+ plasma cells and other 
major populations, although a significantly 
higher expression of Ig k light chains was 
found in responders. Different results were 
instead obtained by Onno Teng et al. (68) 
who, in an independent study (25 patients), 
was able to observe a significantly lower 
distribution of different baseline B cell 
populations (CD20+ B cells, CD79a+ B 
cells and CD138+ plasma cells) in good 
responders. Patients displaying low ex-
pression of CD79a in the synovium had a 
significantly lower risk for a moderate or 
no response.
It is clear from this rapid overview on syn-
ovial predictors of response to Rituximab 
that available data are far from being con-
clusive. Although this might depend on the 
small samples size of the studied popula-
tions, other factors should be considered. 
These include a possible confounding 
effect derived from the high functional 
heterogeneity of B cells (not easy to be 
captured histologically) or the fact that 
Rituximab may act primarily outside of 
the joint, exerting only an indirect action 
in the synovium (69-71). Large multi-cen-
tre randomized clinical trials in anti-TNF 
inadequate responders focused on syno-
vial biopsy are currently ongoing and are 
expected to provide more definite results 
(http://www.r4ra-nihr.whri.qmul.ac.uk).
n	 DRUG TAPERING 
AND WITHDRAWAL: 
DEVELOPMENT OF 
PROGNOSTIC BIOMARKERS 
OF REMISSION STABILITY
Early diagnosis and treatment, better mon-
itoring strategies and the availability of 
different biologic therapies have consid-
erably improved the outcome of chronic 
inflammatory arthritis in recent years, with 
the achievement of stable remission in a 
sizable proportion of the cases. If, on the 
one hand, these progresses have changed 
patients’ health and societal perspec-
tives, on the other they have introduced 
new challenges. In particular, it remains 
undetermined in which patients achiev-
ing remission, treatments can be tapered 
or withdrawn with maintenance of health. 
This question, of fundamental relevance 
in clinical terms, has deep pathobiologi-
cal roots. Indeed, differently from other 
diseases, such as cancers or infectious con-
ditions in which the primary pathogenic 
elements can be tracked, the constructs 
remission, resolution and cure can be dif-
ficult to put into practice in RA or SpA due 
to lack of knowledge about basic disease 
processes. Thus, although several studies 
have contributed to refining the concept of 
clinical remission, the characterization of 
remission in pathobiological terms is still 
largely incomplete. In keeping with this 
goal, beside the growing number of stud-
ies that have investigated remission stabil-
ity after drug tapering/suspension through 
clinical and imaging approaches (72-77), 
there is now increasing interest in address-
ing this issue also from the histopathologi-
cal perspective. 
In a recent exploratory study, Ramirez et 
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al. (78) analysed by US-guided biopsy the 
histopathological features of power Dop-
pler (PD) positive synovitis in 20 RA pa-
tients treated with synthetic or biologic dis-
ease-modifying anti-rheumatic drugs who 
achieved stable DAS28 remission with no 
tender and swollen joints. Progression to 
symptomatic, clinically active disease dur-
ing a follow-up of 12 months was observed 
under treatment in 8 out of 20 patients and 
was associated with the degree of residual 
CD20+ B cell and mast cell infiltration. 
These data suggest a potential role of syno-
vial histopathology for deeper stratification 
of PD positive clinical remission, thus in 
the presence of US-detectable sub-clinical 
inflammation. Another fundamental issue 
is, however, the analysis of the role of syn-
ovial histopathology in the stratification of 
PD negative clinical remission. In this con-
text, recent data published by Alivernini et 
al. (79, 80) have offered important insights, 
suggesting the possibility of disease-relat-
ed differences. In particular, as inferred by 
a cross-sectional analysis in patients un-
der TNF inhibition, PD negative patients 
with PsA in clinical remission can display 
significantly higher degrees of residual in-
flammation (macrophages, T cells and vas-
cular structures) than PD negative patients 
with RA in remission, despite comparable 
clinical characteristics. Prospective stud-
ies performing treatment tapering or dis-
continuation, based on the combination of 
clinical, US and histological selection cri-
teria are expected to define the prognostic 
significance of these observations.
n	 CONCLUSIONS
Chronic inflammatory arthritides are char-
acterized by a degree of phenotypic hetero-
geneity whose pathologic substrate remains 
largely undetermined. This is reflected in 
prognostic variability and variability in re-
sponse to treatments. Currently available 
prediction tools remain unsatisfactory and 
do not allow to deal entirely with such com-
plexity. Synovial tissue analysis has been 
an essential tool to improve our under-
standing of arthritis pathogenesis and for 
the development of new treatments. While 
developments in this direction should be 
still considered a priority, one of the next 
steps will be to define its applicability in 
real-life clinical practice.
Data presented in this review emphasize 
two main concepts: 
1) the existence of a large amount of data 
that would actually support the possible 
exploitation of synovial pathology for 
diagnostic and prognostic purposes in 
different phases of disease progression; 
2) the discrepancy between the amount 
of data generated so far and their poor 
exploitation by physicians and pa-
tients (81).
To explain in part this discrepancy there are 
some aspects of the approach to synovial 
tissue collection that should be considered. 
Firstly, synovial biopsy, although “mini”, 
remains an invasive procedure that re-
quires training, skills and facilities. Bio-
markers eventually derived from synovial 
tissue need therefore to be characterized 
by high performance to be attractive. 
Secondly, current biopsy techniques do 
not guarantee uniform sampling efficien-
cy across all joints and disease activity 
phases. Although large and small joints 
can be biopsied, the output is variable 
and can be influenced by several anatom-
ic and disease-related factors (48). In the 
absence of highly trained operators, this 
may restrict applicability to a proportion 
of candidate subjects. Further technical 
developments in the biopsy procedure, 
the institution of international training 
programs and the validation of candidate 
biomarkers in prospective multicentre 
studies based on large populations are 
likely to promote translational develop-
ment of the field.
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